
Severe COVID-19 infection in a patient with a blastic transformation of a chronic myeloid leukemia and severe treatment-induced immunosuppression: a case report
Author(s) -
Mounir Louardi,
Sayyed Mehdi,
Fahmaoui Kawtar,
Mansour Akram,
Et-tahir Youness,
Tabat Meryem,
Joutey Tahiri Othmane,
Elkhaouri Imane,
Hanane Ezzouine,
Charra Boubakar,
Camara Marieme,
Mouna Lamchahab,
Asmaa Harrach,
Asmaa Quessar
Publication year - 2020
Publication title -
the pan african medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.287
H-Index - 30
ISSN - 1937-8688
DOI - 10.11604/pamj.supp.2020.37.1.25501
Subject(s) - medicine , immunosuppression , pandemic , covid-19 , myeloid leukemia , cancer , intensive care medicine , pediatrics , immunology , disease , infectious disease (medical specialty)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. At this time of uncertainty, we are struggling to provide appropriate care to hematological cancer patients. We need to weigh the risks and benefits of giving cancer treatment against the odds of infecting them with COVID-19. As hematological cancer patients are immunocompromised and there are high chances of exposure during hospital visits, they can get infected and outcome can be fatal. So in this case report, we intend to discuss the possible impact of the current COVID-19 pandemic on patients with acute leukaemia in terms of diagnosis, chemotherapy, and prophylactic measures.